Hodgkin Lymphoma clinical trials

Explore recruiting hodgkin lymphoma clinical trials.

Recruiting hodgkin lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hodgkin Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

Poland, France, Czechia, Spain, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms

Italy, Germany, Czechia, Spain, France, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)

Austria, Italy, Germany, France, Netherlands, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PREFer: Phase II trial of anti-PD-1 antibody treatment and radiotherapy in early-stage favorable classic Hodgkin lymphoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Germany, France, Italy, Poland, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma

Germany, Denmark, Italy, Netherlands, France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Hodgkin Lymphoma trials by city

Hodgkin Lymphoma in Toronto Hodgkin Lymphoma in Vancouver Hodgkin Lymphoma in Montreal Hodgkin Lymphoma in Calgary Hodgkin Lymphoma in Edmonton Hodgkin Lymphoma in Ottawa Hodgkin Lymphoma in Winnipeg Hodgkin Lymphoma in Quebec City Hodgkin Lymphoma in Hamilton Hodgkin Lymphoma in Kitchener Hodgkin Lymphoma in London Hodgkin Lymphoma in Halifax Hodgkin Lymphoma in New York Hodgkin Lymphoma in Los Angeles Hodgkin Lymphoma in Chicago Hodgkin Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease